Bárbara Laranjeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bárbara Laranjeiro has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Margarida Figueiredo-Dias
Faculty of Medicine, Gynecology Department, University of Coimbra, 3004-504 Coimbra, Portugal
3 shared publications - Mariana Robalo Cordeiro
Faculty of Medicine, Gynecology University Clinic, University of Coimbra, 3000-548 Coimbra, Portugal
3 shared publications - Beatriz Eugenia Ferro
Universidad Icesi, Facultad de Ciencias de la Salud, Cali, Colombia
1 shared publication - Carlota Anjinho Carvalhos
Faculty of Medicine, Gynecology University Clinic, University of Coimbra, 3000-548 Coimbra, Portugal
1 shared publication - Kristina Hundarova
Department of Gynecology, Unidade Local de Saúde de Coimbra, Coimbra, Portugal
1 shared publication - Maria João Carvalho
Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, 3000-548 Coimbra, Portugal
1 shared publication
Latest Publications
- Open Access
- 11 September 2024
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 51 (9) , 204
Exploring Gynecologists/Obstetricians and General Practitioners’ Perspectives on Sexual Health Management among Obstetric Patients: Insights from a National Portuguese Survey
Background: Sexual health (SH) remains a marginalized topic in medical education, posing a challenge to healthcare professionals in providing adequate sexual care. This study aimed to assess the knowledge, clinical experience, training experiences and needs of doctors working in Gynecology/Obstetrics (G/O) and General Practice (GP) regarding sexuality during pregnancy. Methods: A cross-sectional study was conducted from September 2022 to March 2023, inviting Portuguese physicians (G/O and GP) to complete an online questionnaire. Results: Of 366 physicians (50.8% GP; 49.2% G/O) surveyed, the majority were female (85.5%), aged between 24 and 35 years (57.9%) and specialists (56.8%). Nearly all respondents (99.2%) recognized the importance of SH during pregnancy, with 86.6% agreeing that inquiring about sexuality is essential, given that 99.2% believe that pregnancy affects SH. However, despite 66.9% of physicians acknowledging that pregnant value sexuality, 55.2% reported that fewer than 10% pose questions, and only 27.6% of doctors inquire about sexuality. Although 85.0% of the respondents felt completely or partially comfortable discussing sexuality, only 24.6% considered themselves skilled to provide SH counselling, with less than a fifth feeling capable of treating specific sexual dysfunctions. The main difficulties were time constraints (75.7%) and lack of training (70.2%), particularly evident in the GP group. More than a quarter of GP responders and 11% of G/O physicians admitted the lack of education or training in this area. Nearly all responders expressed interest in improving their knowledge, with residency training being the most preferred option. Conclusions: Portuguese physicians recognize the importance of sexuality during pregnancy, but only a minority routinely inquire about it during appointments, referring lack of time and training as the major barriers. The study highlights significant deficiencies in Portuguese GP and G/O practitioners concerning sexual health, emphasizing the urgent need for further training in this area.
- 11 September 2024
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 51 (9) , 204
Open AccessExploring Gynecologists/Obstetricians and General Practitioners’ Perspectives on Sexual Health Management among Obstetric Patients: Insights from a National Portuguese Survey
Background: Sexual health (SH) remains a marginalized topic in medical education, posing a challenge to healthcare professionals in providing adequate sexual care. This study aimed to assess the knowledge, clinical experience, training experiences and needs of doctors working in Gynecology/Obstetrics (G/O) and General Practice (GP) regarding sexuality during pregnancy. Methods: A cross-sectional study was conducted from September 2022 to March 2023, inviting Portuguese physicians (G/O and GP) to complete an online questionnaire. Results: Of 366 physicians (50.8% GP; 49.2% G/O) surveyed, the majority were female (85.5%), aged between 24 and 35 years (57.9%) and specialists (56.8%). Nearly all respondents (99.2%) recognized the importance of SH during pregnancy, with 86.6% agreeing that inquiring about sexuality is essential, given that 99.2% believe that pregnancy affects SH. However, despite 66.9% of physicians acknowledging that pregnant value sexuality, 55.2% reported that fewer than 10% pose questions, and only 27.6% of doctors inquire about sexuality. Although 85.0% of the respondents felt completely or partially comfortable discussing sexuality, only 24.6% considered themselves skilled to provide SH counselling, with less than a fifth feeling capable of treating specific sexual dysfunctions. The main difficulties were time constraints (75.7%) and lack of training (70.2%), particularly evident in the GP group. More than a quarter of GP responders and 11% of G/O physicians admitted the lack of education or training in this area. Nearly all responders expressed interest in improving their knowledge, with residency training being the most preferred option. Conclusions: Portuguese physicians recognize the importance of sexuality during pregnancy, but only a minority routinely inquire about it during appointments, referring lack of time and training as the major barriers. The study highlights significant deficiencies in Portuguese GP and G/O practitioners concerning sexual health, emphasizing the urgent need for further training in this area.
- Open Access
- 2 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8468
Menstrual Blood Stem Cells-Derived Exosomes as Promising Therapeutic Tools in Premature Ovarian Insufficiency Induced by Gonadotoxic Systemic Anticancer Treatment
Gonadotoxicity resulting from systemic and locoregional cancer treatments significantly threatens women’s reproductive health, often culminating in premature ovarian insufficiency. These therapies, particularly alkylating agents and ionizing radiation, induce DNA damage and apoptosis in ovarian follicles, leading to infertility, amenorrhea, and estrogen deficiency, which exacerbate risks of osteoporosis and cardiovascular diseases. Existing fertility preservation methods do not prevent immediate ovarian damage, underscoring the need for innovative protective strategies. Menstrual blood-derived stem cells (MenSC) and their extracellular vesicles (EV) present promising regenerative potential due to their therapeutic cargo delivery and pathway modulation capabilities. Preclinical studies demonstrate that MenSC-derived EV ameliorate premature ovarian insufficiency by inhibiting granulosa cell apoptosis, promoting angiogenesis, and activating pivotal pathways such as SMAD3/AKT/MDM2/P53. However, comprehensive research is imperative to ensure the safety, efficacy, and long-term effects of MenSC-derived EV in clinical practice. In this review, we update the current knowledge and research regarding the use of MenSC-derived EV as a novel therapeutic weapon for ovarian regeneration in the context of gonadotoxicity induced by systemic anticancer treatment.
- 2 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8468
Open AccessMenstrual Blood Stem Cells-Derived Exosomes as Promising Therapeutic Tools in Premature Ovarian Insufficiency Induced by Gonadotoxic Systemic Anticancer Treatment
Gonadotoxicity resulting from systemic and locoregional cancer treatments significantly threatens women’s reproductive health, often culminating in premature ovarian insufficiency. These therapies, particularly alkylating agents and ionizing radiation, induce DNA damage and apoptosis in ovarian follicles, leading to infertility, amenorrhea, and estrogen deficiency, which exacerbate risks of osteoporosis and cardiovascular diseases. Existing fertility preservation methods do not prevent immediate ovarian damage, underscoring the need for innovative protective strategies. Menstrual blood-derived stem cells (MenSC) and their extracellular vesicles (EV) present promising regenerative potential due to their therapeutic cargo delivery and pathway modulation capabilities. Preclinical studies demonstrate that MenSC-derived EV ameliorate premature ovarian insufficiency by inhibiting granulosa cell apoptosis, promoting angiogenesis, and activating pivotal pathways such as SMAD3/AKT/MDM2/P53. However, comprehensive research is imperative to ensure the safety, efficacy, and long-term effects of MenSC-derived EV in clinical practice. In this review, we update the current knowledge and research regarding the use of MenSC-derived EV as a novel therapeutic weapon for ovarian regeneration in the context of gonadotoxicity induced by systemic anticancer treatment.
- Open Access
- 14 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1025
The Concept behind the Suitability of Menstrual Blood-Derived Stem Cells for the Management of Vaginal Atrophy among BRCA Mutation Carriers after RRSO
Risk-reducing bilateral salpingo-oophorectomy (RRSO) is recommended for breast cancer gene 1 (BRCA1) and 2 (BRCA2) mutation carriers. A major consequence of RRSO is surgical menopause associated with severe menopausal symptoms, mostly genitourinary complaints. Due to the inherent breast cancer risk, estrogen-based therapies are generally avoided in these patients. So far, the non-hormonal approaches available are not efficient to successfully treat the disabling vaginal atrophy-related symptoms. In regenerative medicine, mesenchymal stem cells (MSC) are the most frequently used cell type due to their remarkable and regenerative characteristics. Therapies based on MSC have revealed positive outcomes regarding symptoms and signs associated with vaginal atrophy by promoting angiogenesis, vaginal restoration, and the proliferation of vaginal mucosa cells. Menstrual blood-derived stem cells (MenSC) are a novel source of MSC, with promising therapeutic potential directly linked to their high proliferative rates; low immunogenicity; non-invasive, easy, and periodic acquisition; and almost no associated ethical issues. In this review, we update the current knowledge and research regarding the potential value of previously preserved MenSC in the therapy of vaginal atrophy among BRCA mutation carriers subjected to RRSO.
- 14 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1025
Open AccessThe Concept behind the Suitability of Menstrual Blood-Derived Stem Cells for the Management of Vaginal Atrophy among BRCA Mutation Carriers after RRSO
Risk-reducing bilateral salpingo-oophorectomy (RRSO) is recommended for breast cancer gene 1 (BRCA1) and 2 (BRCA2) mutation carriers. A major consequence of RRSO is surgical menopause associated with severe menopausal symptoms, mostly genitourinary complaints. Due to the inherent breast cancer risk, estrogen-based therapies are generally avoided in these patients. So far, the non-hormonal approaches available are not efficient to successfully treat the disabling vaginal atrophy-related symptoms. In regenerative medicine, mesenchymal stem cells (MSC) are the most frequently used cell type due to their remarkable and regenerative characteristics. Therapies based on MSC have revealed positive outcomes regarding symptoms and signs associated with vaginal atrophy by promoting angiogenesis, vaginal restoration, and the proliferation of vaginal mucosa cells. Menstrual blood-derived stem cells (MenSC) are a novel source of MSC, with promising therapeutic potential directly linked to their high proliferative rates; low immunogenicity; non-invasive, easy, and periodic acquisition; and almost no associated ethical issues. In this review, we update the current knowledge and research regarding the potential value of previously preserved MenSC in the therapy of vaginal atrophy among BRCA mutation carriers subjected to RRSO.
- Open Access
- 10 October 2021
- Published by Morressier GmbH
ENDOMETRIOSIS HIDDEN BEHIND MENOPAUSE
PROBLEM STATEMENT Endometriosis, believed to be an estrogen-dependent chronic inflammatory disease, classically affects women of reproductive age. The occurrence of de novo endometriosis diagnosis in postmenopausal women has recently suggested a shift in this paradigm. The pathophysiology and clinical management of this condition remain a challenge. The present study aims to
- 10 October 2021
- Published by Morressier GmbH
Open AccessENDOMETRIOSIS HIDDEN BEHIND MENOPAUSE
PROBLEM STATEMENT Endometriosis, believed to be an estrogen-dependent chronic inflammatory disease, classically affects women of reproductive age. The occurrence of de novo endometriosis diagnosis in postmenopausal women has recently suggested a shift in this paradigm. The pathophysiology and clinical management of this condition remain a challenge. The present study aims to